SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Tangram Doses First Participant in TGM-148 Phase I Trial

Tangram says the first participant in its Phase I study of TGM-148, an investigational RNAi treatment for bleeding disorders, has received a first dose.

Related stories